PacBio reports Q4 EPS (20c), consensus (17c)

Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by the successful launch of new products, disciplined cost management, and strategic progress in our clinical strategy. Despite macroeconomic pressures, we have continued to innovate and expand accessibility to HiFi sequencing,” said Christian Henry, President and CEO of PacBio. “Looking ahead to 2025, while the macro environment remains uncertain, I believe PacBio can return to growth and expand market share as the Vega benchtop platform and SPRQ chemistry enable more researchers, clinical labs, and smaller institutions to harness the power of HiFi sequencing.”